Luxna Biotech Co., Ltd. (President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) today announced that it has entered into a collaboration agreement with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France, hereinafter “Servier”) for drug discovery research in the field of neurological diseases.
